The details about the Phase 1 study announced yesterday are available at:
https://clinicaltrials.gov/show/NCT02941523
Our main objective in this study is to see if NOX66 can make tumours respond to chemotherapy once they have become fully drug-resistant, and to do so using low dosages of chemotherapy.
That’s an ambitious and novel objective, but one that in my opinion is very achievable. And if we achieve that, then it would usher in a new era in the management of cancer – offering greater certainty over the response to chemotherapy, including when all treatment options have been exhausted, and to do so with the promise of being able to avoid significant chemotherapy side-effects.
For further information please download PDF attached:
Download this document
